



Has_circ_0008285/miR-211-5p/SIRT-1 Axis Suppress Ovarian Cancer Cells Progression

Khadijeh Elmizadeh¹, Ali Homaei², Ensiyeh Bahadoran³, Farzaneh Abbasi³, Sahar Moghbelinejad^{4*}

1. Department of Obstetrics and Gynecology, School of Medicine, Qazvin University of Medical Science, Qazvin, Iran.

2. Surgery Department, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.

3. School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.

4. Cellular and Molecular Research Centre, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.

Article type: ABSTRACT

Original Article

The significant functional role of circular RNAs (circRNAs) in the progression of malignant tumors, including ovarian cancer, has been shown in various studies. In this study, we aimed to investigate the abnormal expression of hsa_circ_0008285 and its role in ovarian cancer pathogenesis. Quantitative real time polymerase chain reaction (qRT-PCR) and Western blot methods were used to detect the expression of hsa_circ_0008285 and some target genes in ovarian cancer tissues and related cell lines. To determine the functional roles of hsa_circ_0008285 in ovarian cancer, cell proliferation, apoptosis, and cell invasion assays were performed. Bioinformatics (Target scan, circ intractome) and luciferase reporter analyses were used to predict target genes. Results: In the present study, we first found that hsa_circ_0008285 was up regulated in ovarian cancer tissues and related cell lines. Bioinformatics, experimental data, and luciferase reporter analysis data showed miR-211-5p is a direct target of hsa_circ_0008285, while SIRT-1 is a direct target of miR-211-5p. Overexpression of hsa_circ_0008285 in cancer cells increased the expression of SIRT-1 and progression of cancer cells. Based on these results, inhibition of hsa_circ_0008285 expression could cause upregulation of miR-211-5p and down regulation of SIRT-1 and inhibited the proliferation and invasion of ovarian cancer cells. Conclusion: The results of the present study revealed that hsa_circ_0008285 suppressed ovarian cancer progression by regulating miR-211-5p expression to inhibit SIRT-1 expression.

Received:

2024.01.10

Revised:

2024.03.16

Accepted:

2024.04.06

Keywords: Hsa_circ_0008285, ovarian cancer, miR-211-5p, SIRT-1

Cite this article: Elmizadeh K, *et al.* Has_circ_0008285/ miR-211-5p/ SIRT-1 Axis Suppress Ovarian Cancer cells Progression. International Journal of Molecular and Cellular Medicine. 2023; 12(4):401-422 DOI: 10.22088/IJMCM.BUMS.12.4.401.

*Corresponding: Sahar Moghbelinejad

Address: Qazvin University of Medical Sciences, Qazvin, Iran.

E-mail: smoghbelinejad@qums.ac.ir



© The Author(s).

Publisher: Babol University of Medical Sciences

This work is published as an open access article distributed under the terms of the Creative Commons Attribution 4.0 License (<http://creativecommons.org/licenses/by-nc/4>). Non-commercial uses of the work are permitted, provided the original work is properly cited.

Introduction

Ovarian cancer is the deadliest gynecological malignancy and accounts for 5% of estimated cancer deaths (1–3). Females of all ages can develop ovarian carcinogenesis, but most cases are detected in postmenopausal women, and more than 75% of diagnosed cases are at an advanced stage. Late diagnosis is due to the lack of early detection screening, asymptomatic nature at early stages, and vague symptoms of late-stage disease (4,5). Despite continuous advancements in surgery and chemotherapy, the 5-year overall global survival rate of ovarian cancer is approximately 40% (6). Therefore, there is a pressing need to identify the molecular mechanisms underlying the occurrence and development of ovarian cancer for early diagnosis and targeted therapy.

Circular RNAs (circRNAs) are a class of non-coding regulatory RNAs that are mainly formed through the back-splicing of pre-mRNA (7,8). CircRNAs exhibit closed stable ring structures without free 3' and 5' ends, which protect them from RNA exonuclease and degradation (9). They are widely distributed in almost all eukaryotic cells and remain stable in blood, urine, saliva, and other body fluids (10). In this way, they have the potential to be used as novel biomarkers and therapeutic targets for cancer diagnosis and treatment (11).

CircRNAs mainly play a role in gene expression by sponging microRNA (12), while they can also regulate transcription and translation (13,14), facilitating interactions between two or more proteins by acting as an enzyme scaffold between them (15) and encoding oncogenic proteins (16). Several studies have suggested that circular RNAs are up regulated or down regulated and act as tumor suppressors or oncogenes in almost all types of cancers, including ovarian cancer (17,18). For example, circ-NOLC1 promotes ovarian cancer tumorigenesis and development by binding and modulating ESRP1, CDK1, and RhoA levels (19). Circular RNA 0051240 promotes cell proliferation, migration, and invasion in ovarian cancer through the miR-637/KLK4 axis (20). In contrast, circ_0078607 via sponging miR-518a-5p inhibits ovarian cancer invasion and promotes apoptosis of ovarian cancer cells (21), and circ_0061140 sponges miR-761, decreases proliferation and migration and increases apoptosis of ovarian cancer through the miR-136/CBX2 axis (22).

Circ_0008285 is derived from the coding gene chromodomain y-like protein and is 667 nucleotides long. The level of circ-0008285 has been reported to increase in hepatocellular carcinoma (23), mantle cell lymphoma (24), cervical cancer (25), breast cancer (26), and multiple myeloma (27), but decrease in colon cancer (28), bladder cancer (29), and Wilms tumor (30). The mechanisms of action of circ_0008285 in ovarian cancer are not fully understood. In the present study, we characterized circRNA transcripts using RNA sequencing (RNA-seq) analyses of ribosomal RNA-depleted total RNA from nine pairs of ovarian cancer and adjacent non-cancerous tissue samples. Finally, we discovered that *hsa_circ_0008285* was relatively overexpressed in ovarian cancer tissues. We subsequently expanded the sample size and detected *hsa_circ_0008285* expression, and found that its expression level in ovarian cancer was significantly higher than that in adjacent non-tumorous tissues. Therefore, we further explored the underlying functions of *hsa_circ_0008285* in ovarian cancer cells and speculated that overexpression of *hsa_circ_0008285* could serve as a sponge of miR-211-5p to elevate SIRT-1 expression and cause high proliferation and invasion of ovarian cancer cells.

Materials and methods

Patients and clinical tissues

This project was approved by the Ethics Committee of the Qazvin University of Medical Sciences (IR.QUMS.REC.1400.475). Ovarian cancer and adjacent normal tissue samples were collected from patients diagnosed with epithelial ovarian cancer who received surgical treatment at Kowsar Hospital, Qazvin, IRAN. All the enrolled patients signed informed consent forms in compliance with the Declaration of Helsinki. None of the patients had undergone chemotherapy or radiotherapy prior to the surgery. All tissues were immersed in liquid nitrogen and preserved at -80°C .

Cell culture

Ovarian cancer cell lines (SKOV3, A2780) and a normal ovarian cell line (OCE1) were purchased from the Institute Pasteur Tehran, IRAN. The cells cultured in DMEM supplemented with 10% FBS (Gibco, Grand Island, NY, USA), 100 mg/mL penicillin, and streptomycin (Invitrogen). All the cells were maintained in an incubator with 5% CO_2 and saturated humidity at 37°C .

RNA-seq analysis and identification of circRNAs

First, small RNAs was purified according to the manufacturer's instructions. Illumina Small RNA v1.5 Sample Preparation kit (Illumina, Inc.). Sequencing was done by HiSeq 2000 (Illumina, San Diego, CA, USA). Our sequences were mapped to the respective reference genome using BOWTIE2 version 2.2.5 (GRCH 37. p13 NCBI). MaxEntScan33 was used to evaluate the splicing sites. We used BWA-mem to estimate the expression of circRNA.

RNA extraction and quantitative real time polymerase chain reaction (qRT-PCR)

RNA isolation from tissues and the indicated cell lines was performed using TRIzol reagent (Invitrogen Life Technology Co, USA). To evaluate the concentration and purity of the RNA, we used a Nano Drop w ND-1000. First-strand complementary DNA (cDNA) synthesis was performed on 500ng of treated RNA using the Revert Aid First Strand cDNA Synthesis Kit (Thermo Scientific, Fermentas, Waltham, MA, USA). For the quantification of expression, qRT-PCR was performed using GAPDH as an internal control.

The reactions were incubated in a 72-well optical strip at 95°C for 15 min (enzyme activation), followed by 95°C for 20 s and 60°C for 60 s (40 cycles). All reactions were performed in triplicate. After these reactions, the mean Ct was determined from triplicate PCRs. We used the $2^{-\Delta\text{Ct}}$ method to quantify gene expression.

Cell transfection

The synthetic circ-0008285 sequence was subcloned into the pcDNA3.1 vector (Invitrogen). In addition, we ordered the miR-211-5p mimic and inhibitor from the company. SIRT1 overexpressing, empty plasmid, SIRT1 short interference RNA (siRNA), and control siRNA were purchased (Exiqon, Denmark). Lipofectamine 3000 was used to transfect the cells according to the manufacturer's instructions (Invitrogen; Thermo Fisher Scientific, Inc.). Quantitative real-time PCR (qRT-PCR) was used to evaluate the transfection efficiency.

CCK-8 assay

SKOV3 and A2780 cells were harvested in a logarithmic growth phase. The cell density was adjusted to $1 \times 10^3/\text{ml}$ and incubated in 96 well plates (100 μL of cell suspension per well). The 96 well plates were

then placed in an incubator to continue the culture. Then, 10 μ L of CCK-8 reagent (Dojindo, Japan) was added to the wells at 12, 24, 48, and 72 h, followed by 2 h of culture. Subsequently, the absorbance of each well was measured at 450 nm using a microplate reader. Experiments were repeated three times.

Western blotting method

Cultured SKOV3 and A2780 cells were centrifuged. Total protein was extracted from cells using lysis buffer (Beyotime Institute of Biotechnology). The total protein was quantified using a bicinchoninic acid kit (Beyotime Institute of Biotechnology). Subsequently, 40 μ g of total protein was loaded per lane on a 10% SDS-PAGE gel, electroblotted onto polyvinylidene difluoride membranes (Thermo Fisher Scientific, Inc.), and blocked with 5% skimmed milk (Millipore Sigma) for 1 h at room temperature. The membranes were then incubated overnight at 4°C with the following primary antibodies: Anti-SIRT1 (1:1,000 dilution; cat. no. ab110304), Anti-Caspase-3 (1:1000 dilution; cat. no. ab 4051), Anti-Beta actin (1:1000 dilution; cat. no. ab 119716) (Abcam, USA).

Dual-luciferase reporter gene assay

The 3'-UTR of SIRT1 gene containing the sequence of miR-211-5P response element (SIRT1-3'-UTR) and its corresponding mutant sequence lacking any complementarity with miR-211-5P, to be used as negative control, were amplified by PCR. They were then cloned downstream of Renilla luciferase in pGL-3 (E1771, Promega, Madison, WI) vector (Promega, USA), giving rise to SIRT1 3'-UTR pGL-3 and SIRT1-mutant- pGL-3 plasmids. Studied cell lines were seeded into 12-wells plates and co-transfected with the above plasmids along with miR-211-5P mimic, miR-211-5P inhibitor and their NCs using PEI. Meanwhile, transfection with a cloned pGL-3 plasmid either alone, or together with miR-211-5P was performed as control. Cells were also exposed to mock transfection (treatment with PEI transfection reagent alone). After 4 h, DMEM-F12 containing 1 % penicillin-streptomycin and 10 % FBS was added to each well. Subsequently, cells were harvested after 48 h and assayed with a Dual Luciferase assay kit (Promega, USA) according to the manufacturer's instructions. Each value of luminator from the Renilla luciferase was normalized to the Firefly luciferase value.

Analysis of apoptosis

Flow cytometry was used to evaluate apoptosis. In this method, two dyes were used to distinguish apoptotic cells from necrotic cells (Annexin V-FITC and propidium iodide (PI)). Apoptotic cells were Annexin V-FITC-positive, PI-positive, and necrotic cells were Annexin V-FITC-negative, and PI-positive. To do this process, 1.5×10^5 cells/well were plated in 6-multiwell plates with or without 50 μ M metformin. After 48 h, the cells were detached and analyzed by flow cytometry method. The experiment was carried out according to the Life Technologies Apoptosis Assay protocol, and the samples were analyzed by flow cytometry within 1 h using a FACS Caliber (Becton Dickinson, CA) in triplicate. Dot plot graphs were used to illustrate viable cells (lower left quadrant), early-phase apoptotic cells (lower right quadrant), late-phase apoptotic or dead cells (upper right quadrant), and necrotic cells (upper left quadrant).

Statistical analysis

Data analysis was performed using Graph Pad Prism 7 (Graph Pad PRISM V 5.04 analytical software). All data are expressed as mean \pm SD. The mean differences between the two groups were analyzed by

Student's t-test, and more groups by One-way analysis of variance (ANOVA). Differences were considered statistically significant at $P < 0.05$.

Results

Expression detection results

To evaluate *hsa_circ_0008285* expression in tumor tissues and cell lines, qRT-PCR analysis was performed on 35 tumor tissues, 35 adjacent normal tissues, and three cell lines. Our results demonstrated that the expression rate of *hsa_circ_0008285* was markedly increased in ovarian cancer tissues (5.8 ± 0.98) relative to their non-cancerous counterparts (2.3 ± 0.54) (Figure 1a).








Fig. 1. Upregulation of *circ-0008285* in ovarian cancer tissues and cell lines. (a) Expression ratio of *circ-0008285* in 35 cancer tissues and adjacent normal tissues. (b) Expression ratio of *circ-0008285* in SKOV3 and A2780 cell lines. (c) Correlation expression of *circ-0008285* between tissues and cell lines ($R=0.43$, $P<0.001$). Error bars represent mean \pm Standard deviation (SD). *** $p<0.001$.




In addition, significant upregulation of *has_circ_0008285* was seen in the SKOV3 cell line (4.26 ± 0.43) and in the A2780 cell line (4.16 ± 0.65) in comparison to normal ovary cell line (OCE4) (1.76 ± 0.45) ($P=0.004$) (Fig. 1b). We also detected a significant correlation between *has_circ_0008285* expression in cancer tissues and cell lines ($R=0.43$, $P<0.001$) (Fig. 1c).

Promotion of apoptosis in overexpressed Circ-0008285 ovarian cancer cells

To evaluate the role of *has_circ_0008285* in ovarian cancer cell behavior, SKOV3 and A2780 cell lines were transfected with siRNA targeting circ-0008285. qRT-PCR results indicated that *has_circ_0008285* was effectively downregulated in transfected SKOV3 cells (2.2 ± 0.98) in comparison to untransfected cells (5.87 ± 0.98) ($P=0.0002$) (Figure 2a), also we saw significant down regulation in A2780 transfected cell line (1.8 ± 0.54) compared to untransfected cells (5.4 ± 0.89) ($P=0.0077$) (Fig. 2b). Our CCK-8 experiment results showed under expression of *has_circ_0008285* significantly inhibited the proliferation of ovarian cancer cells (Figure 2c, d). In addition, flow cytometry results in the SKOV3 transfected cell line showed a significant increase in the apoptosis rate of transfected cells (27%) compared to untransfected cells (% 18.2) ($p<0.0001$) (Fig. 2e), and an increase in the A2780 cell line (29.2% versus 17.8%) ($p<0.0001$) (Fig. 2f). Results from western blot showed in SKOV3 and A2780 cells with under expression of *has_circ_0008285* there was increased in expression of cleaved-caspase 3 protein level dramatically (Figure 2g). Based on these results, we conclude that the down-regulation of *has_circ_0008285* suppresses proliferation and promotes apoptosis of ovarian cancer cells.











Fig. 2. Circ-0008285 downregulation suppressed cell proliferation and promoted apoptosis. (a) Expression ratio of circ-0008285 after transfection with inh- circ-0008285 in SKOV3 cell line. (b) Expression ratio of circ-0008285 after transfection with inh- circ-0008285 in A2780 cell line. (c) Down-regulation of circ-0008285 caused cell proliferation suppression in SKOV3. (d) Down-regulation of circ-0008285 caused cell proliferation suppression in the A2780 cell line. (e) Under expression of circ-0008285 increases the apoptosis rate of the SKOV3 cell line. (f) Under expression of circ-0008285 increased apoptosis rate of the A2780 cell line (Apoptosis was evaluated by FACS analysis, the different quadrants report the percentage of cells. Non-viable necrotic cells, upper left (Q1), late apoptotic cells, top right (Q2), early apoptotic cells, bottom right (Q3), viable cells lower left (Q4). The experiment was repeated three times and the results were always similar.) (g) Under expression of circ-0008285 increased Caspase protein expression in transfected SKOV3 and A2780 cell lines. Error bars represent the mean of three separate determinations \pm SD. * $p < 0.05$. ** $p < 0.01$. *** $p < 0.001$.


Luciferase assay results

Based on our Bioinformatics and database analysis results (circintractome), the three miRNAs with the highest binding sites for *has_circ_0008285* were miR-211-5p, miR-519e, and miR-384. We evaluated the expression of these miRNAs in ovarian cancer patient tissues and found that miR-211-5p expression was significantly downregulated in cancer tissues (0.89 ± 0.12) in comparison to normal adjacent tissue (3.5 ± 0.22) ($P < 0.0001$) (Figure 3a), and this downregulation was observed in the studied cell lines (Figure 3b) ($P < 0.001$), whereas miR-519e and miR-384 showed no significant difference in expression between ovarian cancerous tissue and adjacent normal tissues. Primer sequences mentioned in Table 1.


(A)



(B)



(C)






Fig. 3. Circ_0008285 is directly bound to miR-211-5p in ovarian cancer cells. (a) Relative expression levels of miR-211-5p were detected by qRT-PCR in 35 ovarian cancer tissues and paired adjacent normal tissues. (b) Relative expression levels of miR-211-5p were detected by qRT-PCR in SKOV3 and A2780 cell lines. (c) Dual-luciferase reporter assays were performed to detect the correlation between miR-211-5p and circ_0008285 in SKOV3 cell line (d) and A2780 cell line. (e) MiR-211-5p inhibition promoted the proliferation of SKOV3 and (f) A2780 cells. Error bars represent mean \pm SD. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Table 1. Primer sequences of studied genes and RNAs.

Gene	Primer Sequences
Has_circ_0008285_divergent-F	TCATAGCCTTTCCACCGA
Has_circ_0008285_divergent-R	ACAGTGCACCCGAAGTG
Has_circ_0008285_convergent-F	ACCTCTCCTAAGGCACTGGT
Has_circ_0008285_convergent-R	GGTCCAGTTTCTCAGGGCTC
MiR-211-5P	F GATGCTGTAATGGATGATATGA R ATTGGAACGATACAGAGAAGATT
SIRT-1	F TGCTGGCCTAATAGAGTGGCA R CTCAGCGCCATGGAAAATGT
GAPDH	F GTCTCCTCTGACTTCAACAGCG R ACCACCCTGTTGCTGTAGCCAA

A Dual-Luciferase Reporter Assay was performed to evaluate the interaction between circ-0008285 and miR-211-5p. The results demonstrated that miR-211-5p significantly decreased the luciferase activity of wild-type circ-0008285(WT), whereas miR-211-5p had no effect on mutant circ-0008285 (Mut) in SKOV3 and A2780 cells ($P < 0.0001$) (Figure 3c, d). A diagrammatic sketch of the potential binding sites obtained from the bioinformatics analysis of miR-211-5p in circ_0008285 is shown in Table 2.

Evaluation of the regulatory actions of miR-211-5p in ovarian cancer cell lines showed that under expression of miR-211-5p dramatically promoted the proliferation of ovarian cancer cells, whereas overexpression of miR-211-5p inhibited the proliferation of ovarian cancer cells (Fig. 3e, f). Thus, the binding ability between circ-0008285 and miR-211-5p was verified.

Table 2. The diagrammatic sketch of the potential binding sites between miR-211-5p and circ_0008285



hsa_circ_0008285 vs miRNA-211-5p	
Score	158
Energy	-15.37 kCal/mol
Position	20.41
miRNA-211-5p	3 UCCGCUUCCUACUGUUUCCCUU5
has_circ_0008285	5 AAAGGAAAAATAAAAAAGGGAA3

MiR-211-5p negatively regulated SIRT-1 in ovarian cancer cells


The downstream target of miR-211-5p was predicted by Target Scan and SIRT-1 was selected for further assays. Bioinformatics analysis suggested that SIRT-1 mRNA harbored a putative miR-211-5p binding site in its 3'-UTR. Additionally, we found that SIRT-1 mRNA expression significantly increased in ovarian cancer tissues (3.7 ± 0.99) compared with that in adjacent normal tissues (1.7 ± 0.87) ($P < 0.0001$), (Figure 4a).

We used the Dual-Luciferase Reporter Assay to further explore whether miR-211-5p directly regulates SIRT-1 expression via interaction with its 3'-UTR. We then constructed wild-type and mutant SIRT-1 3'-


UTR reporter plasmids, SKOV3 and A2780 cells were co-transfected with miR-211-5p or scramble, and wild-type SIRT-1 or mutated SIRT-1, respectively. The results indicated that miR-211-5p significantly decreased the luciferase intensity in wild-type SIRT-1, whereas miR-211-5p could not change the luciferase intensity of the mutant SIRT-1 group (Figure 4b, c). In addition, SIRT-1 mRNA and protein expression were down regulated in miR-211-5p overexpressed ovarian cancer cell lines and up regulated in ovarian cancer cell lines with low expression miR-211-5p (Figure 4d, e). We concluded that miR-211-5p negatively regulated SIRT-1 in ovarian cancer cells.



(C)



(D)



(E)





Fig. 4. MiR-211-5p negatively regulated the SIRT-1 gene in ovarian cancer cells. (a) Relative expression levels of Sirt-1 were detected by qRT-PCR in 35 ovarian cancer tissues and paired adjacent normal tissues. (b) Dual-luciferase reporter assays were performed to detect the correlation between miR-211-5p and Sirt-1 gene in SKOV3 and (c) A2780 cell line. (d) Sirt-1 expression ratio in SKOV3 cell line after miR-211-5p mimic transfection (e) and in A2780 cell line. Error bars represent mean \pm SD. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$


Sponging of miR-211-5p by Circ-0008285 increased SIRT-1 expression

In other sections, our real-time PCR and Western blot data showed that inhibition of *has_circ_0008285* could decrease the expression of SIRT-1 which was upregulated with downregulation of miR-211-5p in ovarian cancer cell lines (Figure 5a, b). We assumed that *has_circ_0008285* was involved in enhancing the expression of SIRT-1 (a downstream target of miR-211-5p) by functioning as a miR-211-5p sponge.

(A)



(B)








Fig. 5. Circ_0008285 enhanced SIRT-1 expression via sponging miR-211-5p in ovarian cancer cells. (a,b). The mRNA level of SIRT-1 in SKOV3 and A2780 cells after transfection of mir-211-5p mimic with cDNA and inhibitor of circ-0008285. (c,d). The protein level of SIRT-1 in SKOV3 and A2780 cells after transfection. Error bars represent the mean of three separate determinations \pm standard deviation (SD). ** $p < 0.01$. *** $p < 0.001$.

Circ_0078607 decrease cells proliferation of ovarian cancer cells via regulating miR-211-5p/SIRT-1 signaling

The CKK-8 assay showed that down regulation of *has_circ_0008285* could inhibit the proliferation of ovarian cancer cells (Figure 6 a, b). Our results also showed that *has_circ_0008285* could inhibit the invasion of ovarian cancer cells (Figure 6 c, d). These data confirmed that *has_circ_0008285* could affect the function of miR-211-5p in suppressing ovarian cancer progression.






Fig. 6. Circ_0008285 repressed proliferation of ovarian cancer cells via regulating miR-211-5p/SIRT-1 signaling. (a,b) CCK-8 assay was performed to analyze the proliferation of SKOV3 and A2780 cells under different transfections. (c,d) The trans well assay was performed to detect the invasion of SKOV3 and A2780 cells under different transfections. Error bars represent the mean of three separate determinations \pm standard deviation (SD). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

Discussion

Ovary cancer manifests itself in old age and is one of the women's cancers with a poor prognosis (31). Considering the targeted therapy of cancers that have been made in the treatment of cancers, including ovarian cancer, identifying the molecular pathways involved in the pathogenesis of this disease plays an important role in its treatment (32). The role of circRNAs as a recently identified type of non-coding RNAs in ovarian cancer is also significant (33). In our study, we used the HiSeq 2000 (Illumina, San Diego, CA) sequencing method for 6 pairs of ovarian cancer and adjacent non-cancerous tissue samples. Mapping on the reference genome was done by Top Hat (GRCH37.p13 NCBI). Circ_0008285 was one of the most differentially expressed circRNA and has significant upregulation in tumoral tissues and confirmation of this upregulation was done on the 35 pairs of tumor and normal tissues of ovary for the first time. We also with function assay showed that under expression of circ_0008285 significantly suppressed ovarian cancer cells proliferation and invasion as well as promoted apoptosis of ovarian cancer cells. These results suggested that *hsa_circ_0008285* might act as a new oncogenic circRNA in ovarian cancer progression.

Several studies have shown one of the main roles of circRNAs is the sponging of miRNAs and via this function participate in circRNA, miRNA, and target gene networks for regulating cancer pathogenesis (34–37). Based on circ transcriptome and circbase data miR-211-5p is one of the targets of circ-0008285. About the role of miR-211-5p in the pathogenesis of different cancers several studies were done. Wu et al., 2022 showed that miR-211-5p suppressed the invasion, migration, proliferation, and progression of CRC cells through sponging SPARC-related growth factor pathways (38). Wang et al., 2020 reported miR-211-5p may play a role as a tumor suppressor and prognostic marker in bladder cancer (39). Qin et al., 2020 showed targeting miR-211-5p and the downstream gene ACSL4 will possibly provide novel insight and represents a promising approach to future therapy of HCC patients (40). About the role of this miRNA in the pathogenesis of ovarian cancer Li et al., 2020 reported CircNRIP1 silencing could inhibit the PTX resistance of ovarian cancer via regulating the miR-211-5p/HOXC8 axis, showing that circNRIP1 might be a potential target for ovarian cancer resistance treatment (41). In line with those above studies, our results showed that miR-211-5p was downregulated in ovarian cancer cells and *_circ_0008285* interacted with miR-211-5p as a competing endogenous RNA to inhibit their action in ovarian cancer. Based on the above data till here, we concluded that *has_circ_0008285* might exert an oncogenic role by sponging miR-211-5p in ovarian cancer progression.

SIRT1 is over-expressed in a majority of ovarian cancers (42, 43) implying the role of SIRT1s in ovarian tumorigenesis. High expression of SIRT1 is also associated with malignant transformation of human ovarian tissue and with ovarian carcinoma with poor prognosis (44). Therefore, SIRT1 inhibition appears to be a good strategy to overcome cancer drug resistance and improve therapy. In the newest article, the role of this gene in ovary function and polycystic ovary syndrome (PCOS) has been shown (45). In our study, SIRT-1 was forecasted to be the direct target of miR-211-5p by bioinformatics analysis. RT-PCR showed that SIRT-1 expression was significantly increased in ovarian cancer tissues and was negatively correlated with miR-211-5p expression. In addition, this study demonstrates that down regulation of SIRT-1 could inhibit the proliferation and invasion of ovarian cancer cells and increase the apoptosis of cancer cells. This phenomenon was the same as the effect of circ-0008285 in ovarian cancer cells. We further demonstrated

that miR-211-5p mimics down regulated SIRT-1 mRNA and protein expression while miR-211-5p inhibitor upregulated SIRT-1 mRNA and protein expression in ovarian cancer cells. In addition, the down-regulation of *circ-0008285* could significantly down regulated the expression of SIRT-1 which was over-expressed by miR-211-5p inhibition. So, we speculated that *circ-0008285* acted as a sponge of miR-211-5p and regulated the expression of SIRT-1 in this way. Thus, the *circ-0008285 / miR-211-5p / SIRT-1* network may facilitate a novel aspect of the treatment of patients with ovarian cancer. However, further investigation should be made on nude mice to verify our conclusion in vivo.

Acknowledgments

The authors appreciate all the study participants in this research. This work was supported by the Cellular and molecular research center at Qazvin University of Medical Sciences. (Grant number 40000656). Author Khadijeh Elmizadeh has received research support from the Cellular and Molecular Research Center at Qazvin University of Medical Sciences.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71:209–49.
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin.* 2022;72:7–33.
3. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin.* 2018;68:284–96.
4. Doubeni CA, Doubeni ARB, Myers AE. Diagnosis and Management of Ovarian Cancer (Internet). 2016. Available from: www.aafp.org/afp
5. Yokoi A, Yoshioka Y, Yamamoto Y, Ishikawa M, Ikeda SI, Kato T, et al. Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer. *Nat Commun.* 2017;8.
6. Heindl A, Khan AM, Rodrigues DN, Eason K, Sadanandam A, Orbegoso C, et al. Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity. *Nat Commun.* 2018;9.
7. Meng S, Zhou H, Feng Z, Xu Z, Tang Y, Li P, et al. CircRNA: Functions and properties of a novel potential biomarker for cancer. *Mol Cancer.* BioMed Central Ltd.; 2017.
8. Li X, Yang L, Chen LL. The Biogenesis, Functions, and Challenges of Circular RNAs. *Mol Cell.* Cell Press; 2018. p. 428–42.
9. Chen LL, Yang L. Regulation of circRNA biogenesis. *RNA Biol.* 2015;12:381–8.
10. Cui J, Chen M, Zhang L, Huang S, Xiao F, Zou L. Circular RNAs: Biomarkers of cancer. *Cancer Innovation.* 2022;1:197–206.
11. Zhang H da, Jiang L hong, Sun D wei, Hou J chen, Ji Z ling. CircRNA: a novel type of biomarker for cancer. *Breast Cancer.* Springer Tokyo; 2018.
12. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. *Nature.* 2013;495:384–8.
13. Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. *Nat Struct Mol Biol.* 2015;22:256–64.
14. Wu N, Yuan Z, Du KY, Fang L, Lyu J, Zhang C, et al. Translation of yes-associated protein (YAP) was antagonized by its circular RNA via suppressing the assembly of the translation initiation machinery. *Cell Death Differ.* 2019;26:2758–73.

15. Fang L, Du WW, Awan FM, Dong J, Yang BB. The circular RNA circ-Ccnb1 dissociates Ccnb1/Cdk1 complex suppressing cell invasion and tumorigenesis. *Cancer Lett.* 2019;459:216–26.
16. Peng Y, Xu Y, Zhang X, Deng S, Yuan Y, Luo X, et al. A novel protein AXIN1-295aa encoded by circAXIN1 activates the Wnt/ β -catenin signaling pathway to promote gastric cancer progression. *Mol Cancer.* 2021;20.
17. Kristensen LS, Hansen TB, Venø MT, Kjems J. Circular RNAs in cancer: Opportunities and challenges in the field. *Oncogene.* Nature Publishing Group; 2018. p. 555–65.
18. Ghafouri-Fard S, Khoshbakht T, Hussen BM, Taheri M, Samsami M. Emerging role of circular RNAs in the pathogenesis of ovarian cancer. *Cancer Cell Int. BioMed Central Ltd;* 2022.
19. Chen S, Wu W, Li Q hui, Xie B min, Shen F, Du Y ping, et al. Circ-NOLC1 promotes epithelial ovarian cancer tumorigenesis and progression by binding ESRP1 and modulating CDK1 and RhoA expression. *Cell Death Discov.* 2021;7.
20. Zhang M, Xia B, Xu Y, Zhang Y, Xu J, Lou G. Circular RNA (hsa:circ_0051240) promotes cell proliferation, migration and invasion in ovarian cancer through miR-637/KLK4 axis. *Artif Cells Nanomed Biotechnol.* 2019;47:1224–33.
21. Zhang N, Jin Y, Hu Q, Cheng S, Wang C, Yang Z, et al. Circular RNA hsa_circ_0078607 suppresses ovarian cancer progression by regulating miR-518a-5p/Fas signaling pathway. *J Ovarian Res.* 2020;13.
22. Zhu J, Luo J e., Chen Y, Wu Q. Circ_0061140 knockdown inhibits tumorigenesis and improves PTX sensitivity by regulating miR-136/CBX2 axis in ovarian cancer. *J Ovarian Res.* 2021;14.
23. Peng S, Yi L, Liao L, Bin Y, Qu W, Hu H. Circ_0008285 knockdown represses tumor development by miR-384/RRM2 axis in hepatocellular carcinoma. *Ann Hepatol.* 2022;27.
24. Mei M, Wang Y, Wang Q, Liu Y, Song W, Zhang M. Circcdyl serves as a new biomarker in mantle cell lymphoma and promotes cell proliferation. *Cancer Manag Res.* 2019;11:10215–21.
25. Bai Y, Li X. Hsa_circ_0008285 facilitates the progression of cervical cancer by targeting MiR-211-5p/sox4 axis. *Cancer Manag Res.* 2020;12:3927–36.
26. Liang G, Ling Y, Mehrpour M, Saw PE, Liu Z, Tan W, et al. Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression. *Mol Cancer.* 2020;19.
27. Chen F, Wang X, Fu S, Wang S, Fu Y, Zhang J, et al. Circular RNA circ-CDYL sponges miR-1180 to elevate yes-associated protein in multiple myeloma. *Exp Biol Med.* 2020;245:925–32.
28. Wang J, Luo J, Liu G, Li X. Circular RNA hsa_circ_0008285 inhibits colorectal cancer cell proliferation and migration via the miR-382-5p/PTEN axis. *Biochem Biophys Res Commun.* 2020;527:503–10.
29. Sun J, Zhang H, Tao D, Xie F, Liu F, Gu C, et al. CircCDYL inhibits the expression of C-MYC to suppress cell growth and migration in bladder cancer. *Artif Cells Nanomed Biotechnol.* 2019;47:1349–56.
30. Zhou R, Jia W, Gao X, Deng F, Fu K, Zhao T, et al. CircCDYL Acts as a Tumor Suppressor in Wilms' Tumor by Targeting miR-145-5p. *Front Cell Dev Biol.* 2021;9.
31. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin.* 2016;66:7–30.
32. Zhong Y, Gao D, He S, Shuai C, Peng S. Dysregulated Expression of Long Noncoding RNAs in Ovarian Cancer. *International Journal of Gynecological Cancer.* Lippincott Williams and Wilkins; 2016. p. 1564–70.
33. Li Q hui, Liu Y, Chen S, Zong Z hong, Du Y ping, Sheng X jie, et al. circ-CSPP1 promotes proliferation, invasion and migration of ovarian cancer cells by acting as a miR-1236-3p sponge. *Biomedicine and Pharmacotherapy.* 2019;114.
34. Zhao Z, Ji M, Wang Q, He N, Li Y. Circular RNA Cdr1as Upregulates SCAI to Suppress Cisplatin Resistance in Ovarian Cancer via miR-1270 Suppression. *Mol Ther Nucleic Acids.* 2019;18:24–33.

35. Ning L, Long B, Zhang W, Yu M, Wang S, Cao D, et al. Circular RNA profiling reveals circEXOC6B and circN4BP2L2 as novel prognostic biomarkers in epithelial ovarian cancer. *Int J Oncol.* 2018;53:2637–46.
36. Arnaiz E, Sole C, Manterola L, Iparraguirre L, Otaegui D, Lawrie CH. CircRNAs and cancer: Biomarkers and master regulators. *Semin Cancer Biol.* Academic Press; 2019. p. 90–9.
37. Chen S, Zhao Y. Circular RNAs: Characteristics, function and role in human cancer. *Histol Histopathol. Histology and Histopathology;* 2018. p. 887–93.
38. Retraction: MiR-211-5p Inhibits the Biological Behaviors of Colorectal Cancer via SPARC-Related Growth Factor Pathways (*J Cancer* (2022) 13: 6 (1895-1904) DOI: 10.7150/jca.60269). *J Cancer.* Ivyspring International Publisher; 2022. p. 2418.
39. Wang W, Liu Z, Zhang X, Liu J, Gui J, Cui M, et al. miR-211-5p is down-regulated and a prognostic marker in bladder cancer. *Journal of Gene Medicine.* 2020;22.
40. Qin X, Zhang J, Lin Y, Sun XM, Zhang JN, Cheng ZQ. Identification of MiR-211-5p as a tumor suppressor by targeting ACSL4 in Hepatocellular Carcinoma. *J Transl Med.* 2020;18.
41. Li M, Cai J, Han X, Ren Y. Downregulation of circnrip1 suppresses the paclitaxel resistance of ovarian cancer via regulating the miR-211-5p/HOXC8 axis. *Cancer Manag Res.* 2020;12:9159–71.
42. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. *Pathology.* 2009;41:366–71.
43. Li D, Bi FF, Chen NN, Cao JM, Sun WP, Zhou YM, et al. A novel crosstalk between BRCA1 and sirtuin 1 in ovarian cancer. *Sci Rep.* 2014;4.
44. Hou M, Zuo X, Li C, Zhang Y, Teng Y. Mir-29b Regulates Oxidative Stress by Targeting SIRT1 in Ovarian Cancer Cells. *Cellular Physiology and Biochemistry.* 2018;43:1767–76.
45. Li X, He Y, Wu S, Zhang P, Gan M, Chen L, et al. Regulation of SIRT1 in Ovarian Function: PCOS Treatment. *Curr Issues Mol Biol.* 2023;45:2073–89.